Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  De Biasi, Sara ^a   Cerri, Stefania ^b   Bianchini, Elena ^b   Gibellini, Lara ^a   Persiani, Elisa ^b   Montanari, Gloria ^b   Luppi, Fabrizio ^b   Carbonelli, Cristiano Matteo ^c   Zucchi, Luigi ^c   Bocchino, Marialuisa ^d   Zamparelli, Alessandro Sanduzzi ^d   Vancheri, Carlo ^e   Sgalla, Giacomo ^f   Richeldi, Luca ^f   Cossarizza, Andrea ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Circulating fibrocytes; Endothelial cells; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIBODY; CD14 ANTIBODY; CD19 ANTIBODY; CD3 ANTIBODY; CD309 ANTIBODY; CD309 PROTEIN; CD34 ANTIBODY; CD45 ANTIBODY; COLLAGEN ANTIBODY; COLLAGEN I ANTIBODY; MONOCLONAL ANTIBODY; NINTEDANIB; PIRFENIDONE; UNCLASSIFIED DRUG; VASCULOTROPIN C; PYRIDONE DERIVATIVE; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD BUFFY COAT; BLOOD CELL; BLOOD SAMPLING; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CIRCULATING ENDOTHELIAL CELL; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; FIBROCYTE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; BLOOD; DISEASE COURSE; GENETICS; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PYRIDONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946740603     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0515-0     Document Type: Article

References (39)

1. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King Jr TE, Koch GG, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015;46(1):243-9. doi: 10.1183/09031936.00200614.
2. Richeldi L. Efficacy endpoints for idiopathic pulmonary fibrosis trials. Lancet Respir Med. 2015;3(5):335-7.
3. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159(4):218-27.
4. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-61.
5. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008;40(10):2129-40. doi: 10.1016/j.biocel.2008.02.012.
6. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1(1):71-81.
7. Strieter RM, Keeley EC, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans Am Clin Climatol Assoc. 2009;120:49-59.
8. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci. 2003;60(7):1342-50.
9. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36(4):598-606.
10. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114(3):438-46.
11. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. 2007;353(1):104-8.
12. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001;166(12):7556-62.
13. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol. 2007;82(3):449-56.
14. Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev. 2013;22(130):552-7.
15. Smadja DM, Dorfmuller P, Guerin CL, Bieche I, Badoual C, Boscolo E, et al. Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thromb Haemost. 2014;112(5):1002-13.
16. Malli F, Koutsokera A, Paraskeva E, Zakynthinos E, Papagianni M, Makris D, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PLoS One. 2013;8(1):e53658.
17. Smadja DM, Mauge L, Nunes H, d'Audigier C, Juvin K, Borie R, et al. Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis. 2013;16(1):147-57.
18. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest. 2009;136(5):1364-70.
19. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;169(11):1203-8.
20. Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med. 2004;170(3):242-51.
21. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care. 2011;183(6):788-824.
22. Cossarizza A, Bertoncelli L, Nemes E, Lugli E, Pinti M, Nasi M, et al. T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy. PLoS One. 2012;7(12):e50728.
23. Cossarizza A, Cousin D. Overcoming challenges in cellular analysis: multiparameter analysis of rare cells. Science. 2015;347(6220):443.
24. Guaraldi GZS, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Beghetto B, et al. Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues. HIV Clin Trials. 2013;14(4):140-8.
25. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):588-94.
26. Bournazos S, Fahim A, Hart SP. Identification of fibrocytes in peripheral blood. Am J Respir Crit Care Med. 2009;180(12):1279. Author reply.
27. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax. 2004;59(7):581-5.
28. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209-20.
29. Richeldi L. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014;371(8):783.
30. Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014;15:16.
31. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061-9.
32. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1023-30.
33. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
34. Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 2015;152:18-27.
35. Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2015;11:359-70. doi: 10.2147/TCRM.S69716.
36. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976-85.
37. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15(1):157.
38. Spagnolo P, Sverzellati N, Rossi G, Cavazza A, Tzouvelekis A, Crestani B, et al. Idiopathic pulmonary fibrosis: an update. Ann Med. 2015;47(1):15-27.
39. Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q, et al. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol. Biol. 2015, doi: 10.1165/rcmb.2014-0445OC.